Proteomic profiling reveals pleiotropic antimetabolite activity of triciribine in acute lymphoblastic leukemia

This study characterizes triciribine as a potent, pleiotropic antimetabolite in acute lymphoblastic leukemia that induces cytotoxicity through ADK-dependent metabolism and broad disruption of nucleotide synthesis, DNA replication, and protein translation, suggesting ADK levels as a predictive biomarker for patient stratification.

The Gist

The Big Picture: A "Swiss Army Knife" Drug vs. a Specific Key

Imagine Acute Lymphoblastic Leukemia (ALL) as a chaotic, rapidly multiplying factory of bad cells. For years, doctors have tried to stop these factories by using "keys" designed to fit specific locks (like the Akt signaling pathway, which acts as the factory's main power switch).

Triciribine (TCN) is a drug that scientists thought was just another key for that specific power switch. However, this new study reveals that TCN isn't just a simple key. It's more like a Swiss Army knife that jams the entire factory floor, not just the power switch.

The researchers used advanced "microscopes" (proteomics) to see exactly what happens inside the leukemia cells when they are hit with this drug. Here is what they found:

1. The Drug Doesn't Just Turn Off the Power Switch

For a long time, everyone believed TCN worked by turning off the Akt signal (the power switch).

• The Finding: The study shows that when TCN hits the cell, the power switch (Akt) actually flickers on briefly before things get messy. It doesn't work like a standard "off" switch.
• The Analogy: Imagine trying to stop a car by cutting the ignition. You expect the engine to die immediately. Instead, with TCN, the engine revs up for a second, and then the whole car starts shaking apart because the wheels, the brakes, and the fuel line are all failing at once.

2. The Real Culprit: The "Metabolism" Chaos

Instead of just one target, TCN (specifically its active form, TCN-P) attacks the cell's construction and supply lines.

• The Finding: The drug messes with the cell's ability to build DNA, make proteins, and create energy. It causes a "traffic jam" in the cell's construction zone.
• The Analogy: Think of the leukemia cell as a busy construction site. TCN doesn't just fire the foreman; it steals the bricks, jams the cranes, and cuts the electricity to the tools. The workers (proteins) get confused, the building (DNA) gets damaged, and the whole site grinds to a halt. This is why the drug is called a "pleiotropic antimetabolite"—it attacks many different metabolic processes at the same time.

3. The Secret Ingredient: The "Gatekeeper" (ADK)

This is the most important discovery for future treatments. The drug TCN is like a locked box. It can't do any damage until a specific worker inside the cell unlocks it.

• The Gatekeeper: That worker is a protein called Adenosine Kinase (ADK). ADK takes the drug and turns it into its active, dangerous form (TCN-P).
• The Problem: Some leukemia cells have a lot of ADK (many workers), so they unlock the box quickly and die fast. Other cells have very few ADK workers, so the box stays locked, and the drug doesn't work.
• The Analogy: Imagine TCN is a sleeping bomb. ADK is the timer that wakes it up. If a cell has a high number of timers (high ADK), the bomb goes off immediately. If the cell has no timers (low ADK), the bomb just sits there harmlessly.

4. Why This Matters for Patients

The researchers tested this on real patient samples and found a clear pattern:

• The Test: If a patient's leukemia cells have high levels of the "Gatekeeper" (ADK), they are likely to respond well to Triciribine.
• The Solution: Doctors can now test a patient's blood to see how much ADK they have.
  • High ADK? Give them Triciribine. It will likely work.
  • Low ADK? Triciribine probably won't work, so don't waste time or cause side effects with it.

Summary

This paper changes the story about Triciribine. It's not a "magic bullet" that targets just one bad signal. It's a broad-spectrum disruptor that causes chaos in the cell's construction and supply chains.

However, for this chaos to happen, the cell needs a specific "Gatekeeper" (ADK) to activate the drug. By checking for this Gatekeeper, doctors can finally predict which patients will be saved by this drug and which ones need a different approach. It turns a "one-size-fits-all" guess into a precision strategy.

Technical Summary

1. Problem Statement

Acute Lymphoblastic Leukemia (ALL) is characterized by significant genetic and metabolic heterogeneity, which limits the efficacy of targeted therapies. While antimetabolites remain a cornerstone of ALL treatment, the mechanisms driving differential drug sensitivity are poorly understood.

• The Specific Gap: Triciribine (TCN), a purine analog, has historically been classified as a direct Akt inhibitor. However, clinical trials have yielded limited objective responses, and its mechanism of action remains ambiguous. It often exhibits cytotoxicity exceeding that of canonical PI3K-Akt-mTOR inhibitors, suggesting its activity is not solely dependent on Akt suppression.
• The Need: An unbiased, systems-level approach is required to define the true molecular targets, metabolic dependencies, and biomarkers governing TCN sensitivity in ALL.

2. Methodology

The authors employed an integrated multi-omics proteomic strategy across diverse ALL cellular models (including T-ALL and BCP-ALL lines with varying sensitivities) and primary patient samples.

• Drug Sensitivity Profiling: Utilized existing datasets (FORALL, PRISM) and independent viability assays (sDSS scoring) to compare TCN against canonical Akt inhibitors.
• Time-Course Phosphoproteomics: Analyzed four ALL cell lines at multiple time points (15 min to 6 h) post-TCN treatment to map early kinase signaling dynamics.
• Proteome Integral Solubility Alteration (PISA): A thermal proteome profiling technique used on cell lysates to identify direct protein-ligand interactions. Cells were treated with TCN and its active metabolite, TCN-P, followed by a thermal gradient to detect protein stabilization/destabilization.
• Quantitative Time-Course Proteomics: Measured global protein abundance changes at 6 h and 24 h to assess downstream pathway alterations.
• Metabolite Quantification: Used LC-MS/MS to quantify intracellular and extracellular levels of TCN and TCN-P over time in sensitive vs. resistant cell lines.
• Validation: Employed Western blotting, in-cell CETSA (Cellular Thermal Shift Assay), and pharmacologic inhibition of Adenosine Kinase (ADK) using ABT-702.
• Clinical Correlation: Tested primary ALL and AML patient samples ex vivo and correlated drug sensitivity with ADK expression levels (mRNA and protein).

3. Key Contributions

• Reclassification of Mechanism: The study challenges the dogma that TCN is primarily an Akt inhibitor. Instead, it characterizes TCN as a pleiotropic antimetabolite that disrupts multiple biosynthetic pathways simultaneously.
• Identification of the Active Species: Confirmed that the monophosphorylated metabolite TCN-P is the predominant intracellular species and the biologically active form, requiring Adenosine Kinase (ADK) for activation.
• Biomarker Discovery: Established ADK abundance as the primary determinant of TCN sensitivity, serving as a predictive biomarker for patient stratification.
• Systems-Level Interaction Map: Generated a comprehensive map of TCN-P interacting proteins, revealing a broad impact on nucleotide metabolism, DNA replication, and protein synthesis rather than a single "magic bullet" target.

4. Key Results

A. Distinct Response Profile vs. Akt Inhibitors

• TCN showed potent cytotoxicity across diverse ALL cell lines, often exceeding that of canonical Akt inhibitors (e.g., afuresertib, ipatasertib).
• Correlation analysis showed minimal similarity between TCN and PI3K-Akt-mTOR inhibitors.
• In PTEN-deficient (constitutively active Akt) cells, TCN did not immediately suppress Akt signaling; instead, it caused transient Akt activation followed by delayed suppression.

B. Phosphoproteomic Signatures

• Early treatment (15 min – 3 h) induced inhibition of Cyclin-Dependent Kinases (CDK1, CDK2, CDK4) and activation of mTOR and MAPK signaling pathways.
• This pattern was consistent across sensitive and resistant lines, suggesting these are early stress responses rather than the primary cause of resistance.

C. PISA Profiling and Direct Targets

• PISA identified ADK as the top hit for thermal stabilization, confirming direct interaction.
• Crucially, no significant thermal stabilization of Akt was observed, refuting the direct binding hypothesis.
• TCN-P interacted with a diverse set of proteins involved in:
  • Purine biosynthesis (e.g., APRT, AK5, PRPS, ATIC).
  • DNA replication and repair.
  • Protein translation and folding.
• This supports a model where TCN-P acts as a broad antimetabolite disrupting cellular homeostasis.

D. ADK as the Gatekeeper of Sensitivity

• Correlation: ADK protein levels strongly correlated with TCN sensitivity (sDSS) across 43 ALL cell lines and primary samples.
• Kinetics: In ADK-high (sensitive) cells, intracellular TCN-P accumulated rapidly to high levels. In ADK-low (resistant) cells, TCN-P accumulation was limited despite high extracellular drug concentrations.
• Rescue: Inhibiting ADK with ABT-702 completely rescued TCN-induced cytotoxicity, proving ADK-mediated phosphorylation is essential for activity.
• Clinical Relevance: High ADK expression predicted better response to TCN in primary ALL and AML samples. Interestingly, in AML, high ADK was associated with poor prognosis in standard chemotherapy but suggested potential utility for TCN-based strategies.

E. Downstream Cellular Stress

• TCN treatment led to impaired purine biosynthesis, DNA damage (γ-H2AX induction), translational stress, and cell-cycle arrest.
• Resistant cells exhibited a stronger induction of adaptive survival pathways (e.g., mTORC1, KRAS, inflammatory signaling) compared to sensitive cells, which showed profound suppression of proliferative programs.

5. Significance and Implications

• Mechanistic Clarity: The study resolves the ambiguity surrounding TCN, shifting the paradigm from a specific kinase inhibitor to a broad-spectrum antimetabolite that induces pleiotropic biosynthetic stress.
• Precision Medicine Strategy: The identification of ADK as a predictive biomarker offers a concrete path for patient stratification. Patients with high ADK expression are likely to benefit from TCN therapy, while those with low ADK may require combination strategies to overcome metabolic resistance.
• Clinical Translation: The findings suggest that previous clinical failures of TCN may have been due to insufficient intracellular activation (low ADK in patient blasts) rather than intrinsic target insensitivity. Future trials should prioritize patient selection based on ADK levels.
• Methodological Impact: Demonstrates the power of combining PISA, phosphoproteomics, and quantitative proteomics to deconvolute complex drug mechanisms that single-target assays miss.

In conclusion, this paper redefines triciribine as a potent, ADK-dependent antimetabolite in ALL, providing a robust framework for its re-evaluation in precision oncology.